@Prorata: I totally agree with you. Although RGS has had some solid scientific research (some very good papers published in the last 3 years) and a very interesting product pipeline, the ability to communicate to both potential patients and shareholders as been ... non existent. This problem goes way beyond ASX announcements... How often are RGS scientists producing papers at conferences? How often is the CEO leading corporate and commercial communication? Other biotech startup or non startup have fared better on the ASX market with lesser products.. but they communicate better!
RGS Price at posting:
14.0¢ Sentiment: Hold Disclosure: Held
